NEW YORK (GenomeWeb) – Diagnostics firm Novacyt today reported its sales for the first half of the year jumped 40 percent year over year. The results include contributions from its acquisition of Primerdesign in May 2016.
The company posted €7 million ($8.1 million) in sales for the first six months of 2017, up from €5 million in H1 2016. At constant exchange rates, Novacyt's sales were up 53 percent year over year, it said.
Novaprep sales increased 29 percent to €1.1 million, while Primerdesign sales grew 3 percent to €2.6 million. Lab21 sales rose 17 percent to €3.3 million.
Highlights for the period included a successful registration with the US Food and Drug Administration for the Novaprep HQ+ Orange vial as a Class I medical device for cytology or molecular use.
Also, the China Food and Drug Administration approved the Novaprep system for non-gynecological cancer testing, in addition to an earlier approval for cervical cancer. Novacyt said that it plans to launch the product in 19 new territories in South America and to make additional investments in Asia-Pacific.
The firm signed also a distribution deal with MDxHealth for the SelectMDx Liquid Biopsy Prostate Cancer Test for the UK.
Last month, Novacyt completed a €3 million private financing round. The company added that subsequent to the first half of the year, it achieved its first CE-IVD mark, for a Zika assay, and expects to launch the test shortly.